[12] Patent
[11] Patent No.:GC0007562  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125994
Date of the Decision to Grant the Patent:14/Apr/2018

[21] Application No.:GC 2010-16111

[22] Filing Date:19/6/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
DK
19/6/2009
PCT/DK2009/050134

[72] Inventors:1- Andreas Ritzén،2- Jan Kehler،3- Morten Langgård،4- Jacob Nielsen،5- John Paul Kilburn،6- Mohamed M. Farah

[73] Owner: H. LUNDBECK A/S, 9 Ottiliavej, Valby, DK -2500, Denmark

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
Int. Cl.7: C07D403/12; C07D487/04; A61K31/4184;A61K31/4353;A61K31/519 ;A61P25/00]

[56] Cited Documents:

-WO 2007098169 A (AMGEN INC [US]; MEMORY PHARMACEUTICALS CORPORT [US]; ARRINGTON MARK P) 30 August 2007
-WO 2006070284 A (PFIZER PROD INC [US]; CHAPPIE THOMAS ALLEN [US]; HUMPHREY JOHN MICHAEL) 06 July 2006
-WO 2005082883 A (PFIZER PROD INC [US]; ALLEN MARTIN PATRICK [US]; CHAPPIE THOMAS ALLEN) 09 September 2005
-KEHLER J ET AL: The potential therapeutic use of phosphodiesterase 10 inhibitors EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 17, no. 2, 01 February 2007
-WO 2005003129 A (ALTANA PHARMA AG [DE]; VENNEMANN MATTHIAS [DE]; BAER THOMAS [DE]; BRAU) 13 January 2005
 
Examiner: PH. Sultana K. AlOudah

[54] NOVEL PHENYLIMIDAZOLE DERIVATIVE AS PDE10A ENZYME INHIBITOR
[57] Abstract: This invention provides the compound 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine having the structure and tautomers and pharmaceutically acceptable acid addition salts thereof, and polymorphic forms thereof.
No. of claims: 7


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.